La Jolla Pharmaceutical Company (NASDAQ:LJPC), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, …
by Sonya Colberg The market has recently blasted La Jolla Pharmaceutical Company (NASDAQ:LJPC) shares to mystifying levels, thanks primarily to insider buying. But that …
In a research report published April 20, Oppenheimer analyst Ling Wang initiated coverage on shares of La Jolla Pharmaceutical Company (NASDAQ:LJPC) with an Outperform …
H.C.
In a research report published Tuesday, Chardan Capital analyst Gbola Amusa reiterated a Buy rating on La Jolla Pharmaceutical Company (NASDAQ:LJPC) with a $54 price …
In a research report issued today, H.C.
In a research note issued today, Wedbush analyst Liana Moussatos reiterated an Outperform on La Jolla Pharmaceutical (NASDAQ:LJPC) with a $45 price target …
In a report issued yesterday, Wedbush analyst Liana Moussatos reiterated an Outperform rating on La Jolla Pharaceutical Co. (NASDAQ:LJPC) with a $45 price target, …
In a research note released today, H.C.
In a research note released Tuesday, H.C.
